DRREDDY

launched Obeda, India's first DCGI-approved generic semaglutide injection for type 2 diabetes. This Day-1 launch leverages in-house API and formulation capabilities to provide a cost-effective GLP-1 therapy. The company plans global expansion, targeting the substantial market demand for chronic metabolic and obesity treatments.